About Kura Oncology, Inc.
https://kuraoncology.comKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer.
CEO
Troy Edward Wilson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 132
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Wedbush
Outperform
Mizuho
Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.52M
Value:$89.06M
BVF INC/IL
Shares:8.62M
Value:$80.66M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:8.12M
Value:$75.97M
Summary
Showing Top 3 of 244
About Kura Oncology, Inc.
https://kuraoncology.comKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $20.75M ▲ | $97.53M ▲ | $-74.12M ▼ | -357.19% ▲ | $-0.85 ▼ | $-73.95M ▼ |
| Q2-2025 | $15.29M ▲ | $87.95M ▲ | $-66.12M ▼ | -432.51% ▼ | $-0.75 ▼ | $-65.51M ▼ |
| Q1-2025 | $14.11M ▼ | $78.81M ▲ | $-57.43M ▼ | -407.07% ▼ | $-0.66 ▼ | $-64.7M ▼ |
| Q4-2024 | $53.88M ▲ | $76.34M ▲ | $-19.22M ▲ | -35.66% ▼ | $-0.22 ▲ | $-16.59M ▲ |
| Q3-2024 | $0 | $59.88M | $-54.4M | 0% | $-0.63 | $-53.78M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $549.66M ▼ | $649.38M ▼ | $406.84M ▲ | $242.54M ▼ |
| Q2-2025 | $630.73M ▼ | $682.42M ▼ | $376.94M ▼ | $305.49M ▼ |
| Q1-2025 | $658.19M ▼ | $743.76M ▼ | $379.36M ▲ | $364.41M ▼ |
| Q4-2024 | $727.39M ▲ | $760.16M ▲ | $346.52M ▲ | $413.64M ▼ |
| Q3-2024 | $455.3M | $478.84M | $55.07M | $423.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-74.12M ▼ | $-80.63M ▼ | $93.97M ▲ | $0 ▼ | $13.34M ▼ | $-83.19M ▼ |
| Q2-2025 | $-66.12M ▼ | $-28.78M ▲ | $58.94M ▲ | $515K ▲ | $30.68M ▲ | $-30.23M ▲ |
| Q1-2025 | $-57.43M ▼ | $-71.93M ▼ | $-101.41M ▼ | $143K ▼ | $-173.19M ▼ | $-72.22M ▼ |
| Q4-2024 | $-19.22M ▲ | $269.13M ▲ | $-94.95M ▼ | $806K ▼ | $174.98M ▲ | $268.76M ▲ |
| Q3-2024 | $-54.4M | $-43.44M | $45.53M | $2.2M | $4.3M | $-43.44M |
CEO
Troy Edward Wilson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 132
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Wedbush
Outperform
Mizuho
Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.52M
Value:$89.06M
BVF INC/IL
Shares:8.62M
Value:$80.66M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:8.12M
Value:$75.97M
Summary
Showing Top 3 of 244